J Chirgwin
Overview
Explore the profile of J Chirgwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, et al.
Ann Oncol
. 2021 Aug;
32(10):1256-1266.
PMID: 34384882
Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET)....
2.
Heckel L, Fennell K, Reynolds J, Osborne R, Chirgwin J, Botti M, et al.
Eur J Cancer
. 2015 Jul;
51(14):2049-57.
PMID: 26208461
Aims: The aims of this analysis were to examine levels of unmet needs and depression among carers of people newly diagnosed with cancer and to identify groups who may be...
3.
Yuen E, Dodson S, Batterham R, Knight T, Chirgwin J, Livingston P
Eur J Cancer Care (Engl)
. 2015 Jan;
25(2):294-306.
PMID: 25630765
Caregivers play a vital role in caring for people diagnosed with cancer. However, little is understood about caregivers' capacity to find, understand, appraise and use information to improve health outcomes....
4.
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, et al.
Breast
. 2014 Jan;
23(2):142-51.
PMID: 24393617
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by...
5.
Davis S, Bell R, Wang Y, Hanna F, Davies-Tuck M, Bell R, et al.
Climacteric
. 2012 Nov;
16(6):632-8.
PMID: 23148546
Background: The profound estrogen depletion caused by aromatase inhibitors (AIs) is associated with musculoskeletal symptoms, but the underlying pathophysiology remains unclear. Objective: To assess the effects of AI therapy on...
6.
Rayson D, Suter T, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, et al.
Ann Oncol
. 2011 Nov;
23(7):1780-8.
PMID: 22056854
Background: The cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) in an adjuvant breast cancer treatment regimen is unknown. Patients And Methods: Women with resected node-positive or intermediate-risk...
7.
Chirgwin J, Chua S
Breast
. 2011 Aug;
20(5):394-406.
PMID: 21839635
Background: Monotherapy with nanoparticle albumin-bound (nab)-paclitaxel has demonstrated improved efficacy and safety compared with solvent-based paclitaxel and docetaxel. Design: A comprehensive review of all reported studies of nab-paclitaxel combinations with...
8.
Read J, Pearce J, Li X, MUIRHEAD H, Chirgwin J, Davies C
J Mol Biol
. 2001 May;
309(2):447-63.
PMID: 11371164
Phosphoglucose isomerase (PGI) is a multifunctional protein, which, inside the cell, functions as a housekeeping enzyme of glycolysis and gluconeogenesis and, outside the cell, exerts wholly unrelated cytokine properties. We...
9.
Wang F, Duan R, Chirgwin J, Safe S
J Mol Endocrinol
. 2000 Apr;
24(2):193-202.
PMID: 10750020
Insulin-like growth factor-I (IGF-I), transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) induced cathepsin D gene expression and reporter gene activity in MCF-7 human breast cancer cells transiently...
10.
Kudlicki W, Chirgwin J, Kramer G, Hardesty B
Biochemistry
. 1995 Nov;
34(44):14284-7.
PMID: 7578030
Rhodanese bound to bacterial ribosomes as peptidyl-tRNA can be folded into an enzymatically active conformation by generating C-terminal extensions of the wild-type enzyme. Rhodanese was synthesized by coupled transcription/translation in...